Skip to main content
HealthPartners

Coverage criteria policies

Genetic Testing: Pharmacogenetics

These services may or may not be covered by your HealthPartners plan. Please see your plan documents for your specific coverage information. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage.

Administrative Process

Prior authorization is required for pharmacogenetic testing, except for the following services when associated with procedure and primary diagnosis codes from the list below (under Codes):

  • BRCA1/2 genotyping related to olaparib therapy
  • BRCA1/2 genotyping related to rucaparib therapy
  • CFTR genotyping related to ivacaftor therapy
  • CFTR genotyping related to lumacaftor therapy
  • CYP2C9 genotyping related to siponimod therapy
  • CYP2D6 genotyping related to eliglustat therapy
  • CYP2D6 genotyping related to tetrabenazine therapy
  • HLA-B*1502 genotyping related to carbamazepine therapy
  • HLA-B*1502 genotyping related to phenytoin therapy
  • HLA-B*5701 genotyping related to abacavir therapy
  • HLA-B*5801 genotyping related to allopurinol therapy

Medication coverage is outside the scope of this coverage policy.

Pharmacogenetic testing other than as described below is also subject to a review for medical necessity, based on current clinical literature and expert recommendations, unless listed as an indication that is not covered.

Coverage

Indications that are covered

Single-gene testing related to the following therapies is covered when any criteria below are met:

  • 6-mercaptopurine: TPMT genotyping is covered for inflammatory bowel disease.
  • Abacavir: HLA-B*5701 genotyping is covered. (Prior authorization is not required.)
  • Allopurinol: HLA-B*5801 genotyping is covered. (Prior authorization is not required.)
  • Azathioprine: TPMT genotyping is covered for inflammatory bowel disease.
  • Capecitabine: DPYD genotyping is covered for unusually early, severe, treatment-related toxicity in the first few therapy cycles.
  • Carbamazepine: HLA-B*1502 genotyping is covered. (Prior authorization is not required.)
  • Eliglustat: CYP2D6 genotyping is covered. (Prior authorization is not required.)
  • Fluorouracil: DPYD genotyping is covered for unusually early, severe, treatment-related toxicity in the first few therapy cycles.
  • Irinotecan: UGT1A1 genotyping is covered for elevated serum bilirubin or Gilbert syndrome.
  • Ivacaftor: CFTR genotyping is covered. (Prior authorization is not required.)
  • Lumacaftor: CFTR genotyping is covered. (Prior authorization is not required.)
  • Olaparib: BRCA1/2 genotyping is covered. (Prior authorization is not required.)
  • Phenytoin: HLA-B*1502 genotyping is covered. (Prior authorization is not required.)
  • Rucaparib: BRCA1/2 genotyping is covered. (Prior authorization is not required.)
  • Siponimod: CYP2C9 genotyping is covered. (Prior authorization is not required.)
  • Tetrabenazine: CYP2D6 genotyping is covered. (Prior authorization is not required.)

Indications that are not covered

  1. The following services are considered experimental/investigational because reliable evidence does not permit conclusions concerning safety, effectiveness, or effect on health outcomes:
    1. APOE genotyping
    2. COMT genotyping
    3. KIF6 genotyping
    4. MTHFR genotyping
    5. NUDT15 genotyping
    6. Serotonin receptor (HTR2A and HTR2C) genotyping
    7. SLCO1B1 genotyping
    8. VKORC1 genotyping
    9. Genotyping of CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP2B6, CYP1A2, or genotyping of any other gene in the Cytochrome p450 (CYP450) families for any indication except as described under Indications that are Covered
    10. Multiple-gene pharmacogenetic panels for all indications, including, but not limited to, multiple-gene panels involving one or more genes from the Cytochrome p450 (CYP450) families
    11. Pharmacogenetic testing to inform the selection or dose of medication therapy for management of depression, mood disorders, psychosis, anxiety, attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD), and/or substance use disorder
  2. The following services are not covered and are considered not medically necessary:
    1. Comparative analysis using short tandem repeat (STR) markers that is billed separately, as it is considered to be included as part of the genetic testing.
    2. Direct-to-consumer genetic testing
    3. Genetic testing for acquired disorders (those of non-genetic etiology, such as a condition caused by an identified environmental factor).
    4. Genetic testing that was not ordered by a licensed healthcare provider or physician (see Definitions) who has established a direct patient care relationship with the member to be tested.
    5. Genetic testing that is provided solely to satisfy data collection and analysis needs and that will not be used in direct clinical management.
    6. Predictive genetic testing for asymptomatic members under 18 years of age for conditions generally accepted as having an onset in adulthood.
    7. Repeat testing of a unique analyte (genetic substance) using the same method of analysis.
    8. Multiple-gene panels that include genes not associated with ruling out potential causes for the clinical condition, features, characteristics, or symptoms being evaluated.
  3. Genetic testing is considered not medically necessary when test results will not provide a diagnosis or unifying diagnosis or directly impact the treatment or management of the condition being evaluated.

Definitions

Cytochrome P450 (CYP450) includes multiple genes which affect the metabolism of a variety of drug classifications.

Genotyping is the process of determining which genetic variants an individual possesses.

Healthcare provider is any licensed non-physician (excluding naturopathic providers).

Pharmacogenetic tests (pharmacogenomic tests) analyze genes to identify patients who are likely to respond to a specific drug, those who may not respond, and those likely to have adverse reactions.

Physician is a licensed medical doctor or doctor of osteopathy.

If available, codes for a procedure, device or diagnosis are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all inclusive.

These services do not require prior authorization when associated with pharmacogenetic testing:

Codes

Description

81162

BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis

81163

BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis

81164

BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

81165

BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis

81166

BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

81167

BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

81212

BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants

81215

BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant

81216

BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis

81217

BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant

81220

CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, ACMG/ACOG guidelines)

81221

CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants

81222

CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants

81223

CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence

81224

CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility)

81370

HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1

81371

HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, and -DRB1 (eg, verification typing)

81372

HLA Class I typing, low resolution (eg, antigen equivalents); complete (ie, HLA-A, -B, and -C)

81373

HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each

81374

HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each

81375

HLA Class II typing, low resolution (eg, antigen equivalents); HLA-DRB1/3/4/5 and -DQB1

81376

HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each

81377

HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each

81378

HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A, -B, -C, and -DRB1

81379

HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and -C)

81380

HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each

81381

HLA Class I typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, B*57:01P), each

81382

HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each

81383

HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each

These services do not require prior authorization when associated with any of these primary diagnoses:

E75.22 Gaucher disease

G10 Huntington’s disease

G35 Multiple sclerosis

Prior authorization is required for all other primary diagnoses.

Codes

Description

0070U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)

0071U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence

0072U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene)

0073U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene)

0074U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans)

0075U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5’ gene duplication/multiplication)

0076U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3’ gene duplication/multiplication)

81226

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)

81227

CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)

These services require prior authorization:

Codes

Description

0029U

Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)

0030U

Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)

0031U

CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)

0032U

COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant

0033U

HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])

0034U

TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism), gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)

0070U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)

0071U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence

0072U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene)

0073U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene)

0074U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans)

0075U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5’ gene duplication/multiplication)

0076U

CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3’ gene duplication/multiplication)

0078U

Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder

81225

CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)

81230

CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)

81231

CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)

81232

DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)

81283

IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant

81291

MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)

81306

NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)

81328

SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)

81335

TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variant(s), (eg, *2, *3)

81346

TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)

81350

UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37)

81355

VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variants (eg, -1639G>A, c.173+1000C>T)

81400

MOLECULAR PATHOLOGY PROCEDURE LEVEL 1

81401

MOLECULAR PATHOLOGY PROCEDURE LEVEL 2

81402

MOLECULAR PATHOLOGY PROCEDURE LEVEL 3

81403

MOLECULAR PATHOLOGY PROCEDURE LEVEL 4

81404

MOLECULAR PATHOLOGY PROCEDURE LEVEL 5

81405

MOLECULAR PATHOLOGY PROCEDURE LEVEL 6

81406

MOLECULAR PATHOLOGY PROCEDURE LEVEL 7

81407

MOLECULAR PATHOLOGY PROCEDURE LEVEL 8

81408

MOLECULAR PATHOLOGY PROCEDURE LEVEL 9

81479

Unlisted molecular pathology procedure

81599

Unlisted multianalyte assay with algorithmic analysis

G9143

Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

CPT Copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association

Products

This information is for most, but not all, HealthPartners plans. Please read your plan documents to see if your plan has limits or will not cover some items. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage. These coverage criteria may not apply to Medicare Products if Medicare requires different coverage. For more information regarding Medicare coverage criteria or for a copy of a Medicare coverage policy, contact Member Services at 952-883-7979 or 1-800-233-9645.

References

  1. Becker, M. A., & Perez-Ruiz, F. (2019). Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout. In: N. Dalbeth & P. L. Romain (Eds.). UpToDate. Waltham, MA: UpToDate.
  2. Bradley, P., Shiekh, M., Mehra, V., Vrbicky, K., Layle, S., Olson, M. C., . . . Lukowiak, A. A. (2018). Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. Journal of Psychiatric Research 96, 100-107.
  3. Clancy, J. P., Johnson, S. G., Yee, S. W., McDonagh, E. M., Caudle, K. E., Klein, T. E., . . . Clinical Pharmacogenetics Implementation Consortium. (2014). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clinical Pharmacology and Therapeutics, 95, 592-597.
  4. Eaton, K. D., & Lyman, G. H. (2017). Dosing of anticancer agents in adults. In: P. J. Hesketh & S. R. Vora (Eds.). UpToDate. Waltham, MA: UpToDate.
  5. ECRI Institute. (2016a). Pharmacogenetic testing to guide treatment of chronic pain. Plymouth Meeting, PA: ECRI Institute.
  6. ECRI Institute. (2016b). Proove Opioid Response (Proove Biosciences, Inc.) for predicting clinical response and optimal dosing of opioid medications. Plymouth Meeting, PA: ECRI Institute.
  7. ECRI Institute. (2016c). Proove Opioid Risk (Proove Biosciences, Inc.) for assessing risk of opioid misuse. Plymouth Meeting, PA: ECRI Institute.
  8. ECRI Institute. (2017). LifeKit Predict (Prescient Medicine) for predicting risk of opioid dependency. Plymouth Meeting, PA: ECRI Institute.
  9. ECRI Institute. (2018a). BRACAnalysis CDx (Myriad Genetics, Inc.) for determining eligibility for olaparib (Lynparza) treatment for metastatic breast cancer. Plymouth Meeting, PA: ECRI Institute.
  10. ECRI Institute. (2018b). BRACAnalysis CDx (Myriad Genetics, Inc.) for determining eligibility for PARP inhibitor treatment for ovarian cancer. Plymouth Meeting, PA: ECRI Institute.
  11. ECRI Institute. (2018c). FoundationFocus CDxBRCA (Foundation Medicine, Inc.) for determining eligibility for rucaparib (Rubraca) treatment for ovarian cancer. Plymouth Meeting, PA: ECRI Institute.
  12. ECRI Institute. (2018d). GeneSight Psychotropic Pharmacogenetic Testing (Assurex Health, Inc.) for guiding medication selection for patients with neuropsychiatric disorders. Plymouth Meeting, PA: ECRI Institute.
  13. ECRI Institute. (2018e). Neuro IDgenetix (AltheaDx, Inc.) for guiding medication selection for patients with psychiatric disorders or acute or chronic pain. Plymouth Meeting, PA: ECRI Institute.
  14. Elliott, L. S., Henderson, J. C., Neradilek, M. B., Moyer, N. A., Ashcraft, K. C., & Thirumaran, R. K. (2017). Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One, 12, e0170905.
  15. Flockhart, D A., O’Kane, D., Williams, M. S., Watson, M. S., Flockhart, D. A., Gage, B., . . . ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. (2008). Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine, 10, 139-150.
  16. Gage, B. F., Bass, A. R., Lin, H., Woller, S. C., Stevens, S. M., Al-Hammadi, N., . . . Eby, C. S. (2017). Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: The GIFT randomized clinical trial. JAMA, 318, 1115-1124.
  17. Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., . . . Dechairo, B. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research, 111, 59-67.
  18. Hardinger, K., & Magee, C. C. (2018). Pharmacology of cyclosporins and tacrolimus. In: D. E. Furst, D. C. Brennan, & A. Q. Lam (Eds.). UpToDate. Waltham, MA: UpToDate.
  19. Hayes, Inc. (2017). PGxOne Plus (Admera Health). Philadelphia, PA: Hayes, Inc.
  20. Hayes, Inc. (2018a). CYP2C19 pharmacogenomic genotyping to direct clopidogrel therapy for secondary prevention in patients with a history of stroke and/or transient ischemic attack. Philadelphia, PA: Hayes, Inc.
  21. Hayes, Inc. (2018b). CYP2C19 pharmacogenomic genotyping to direct clopidogrel therapy in adult patients undergoing percutaneous coronary intervention (PCI). Philadelphia, PA: Hayes, Inc.
  22. Hayes, Inc. (2018c). Genetic testing to predict allopurinol toxicity. Philadelphia, PA: Hayes, Inc.
  23. Hayes, Inc. (2018d). MTHFR genetic testing in common clinical conditions. Philadelphia, PA: Hayes, Inc.
  24. Hayes, Inc. (2018e). Pharmacogenomic testing for selected psychiatric and behavioral conditions. Philadelphia, PA: Hayes, Inc.
  25. Hayes, Inc. (2018f). SLCO1B1 pharmacogenomic genotyping for statin dosing or selection. Philadelphia, PA: Hayes, Inc.
  26. Hayes, Inc. (2019a). GeneSight Psychotropic (Assurex Health Inc.). Philadelphia, PA: Hayes, Inc.
  27. Hayes, Inc. (2019b). MTHFR pharmacogenetic genotyping for altering drug treatments. Philadelphia, PA: Hayes, Inc.
  28. Hirsch, M., & Birnbaum, R. J. (2018). Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. In: P. P. Roy-Byrne & D. Solomon (Eds.). UpToDate. Waltham, MA: UpToDate.
  29. Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., . . . Guyatt, G. H. (2012). Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141, e152S-e184S.
  30. Hughes, D. (2018). Gaucher disease: Treatment. In: S. Hahn & E. TePas (Eds.). UpToDate. Waltham, MA: UpToDate.
  31. Hull, R. D., Garcia, D. A., & Vazquez, S. R. (2019). Warfarin and other VKAs: Dosing and adverse effects. In: L. L. K. Leung & J. S. Timauer (Eds.). UpToDate. Waltham, MA: UpToDate.
  32. Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., . . . American College of Rheumatology. (2012). 2012 American College of Rheumatology guidelines for management of gout part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 64, 1431-1446.
  33. Krishnamurthi, S. S. (2018). Enterotoxicity of chemotherapeutic agents. In: R. E. Drews & D. M. F. Savarese (Eds.). UpToDate. Waltham, MA: UpToDate.
  34. MacDermott, R. P. (2017). 6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in patients with inflammatory bowel disease. In: P. Rutgeerts & K. M. Robson (Eds.). UpToDate. Waltham, MA: UpToDate.
  35. Matulonis, U. A., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., . . . Ledermann, J. A. (2016). Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer, 122, 1844-1852.
  36. Matulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira-Frommer, R., Audeh, M. W., . . . Coleman, R. L. (2016). Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety. Annals of Oncology, 27, 1013-1019.
  37. National Comprehensive Cancer Network. (2017a). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 5). Fort Washington, PA: National Comprehensive Cancer Network.
  38. National Comprehensive Cancer Network. (2017b). Rectal cancer (version 4). Fort Washington, PA: National Comprehensive Cancer Network.
  39. National Comprehensive Cancer Network. (2018). Colon cancer (version 1). Fort Washington, PA: National Comprehensive Cancer Network.
  40. Olek, M. J. (2018). Treatment of progressive multiple sclerosis in adults. In: F. Gonzalez-Scarano & J. F. Dashe (Eds.). UpTpDate. Waltham, MA: UpToDate.
  41. Olson, M. C., Maciel, A., Gariepy, J. F., Cullors, A., Saldivar, J., Taylor, D., . . . Vaishnavi, S. (2017). Clinical impact of pharmacogentic-guided treatment for patients exhibiting neuropsychiatric disorders: A randomized clinical trial. Primary Care Companion for CNS Disorders, 19, e1-e7.
  42. Pallet, N., Etienne, I., Buchler, M., Bailly, E., Hurault de Ligny, B., Choukroun, G., . . . Thervet, E. (2016). Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype. American Journal of Transplantation, 16, 2670-2675.
  43. Phillips, E. J., & Mallal, S. A. (2017). Abacavir hypersensitivity reaction. In: J. G. Bartlett & J. MItty (Eds.). UpToDate. Waltham, MA: UpToDate.
  44. Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., . . . Niemi, M. (2014). The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clinical Pharmacology and Therapeutics, 96, 423-428.
  45. Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., . . . Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377, 523-533.
  46. Rosenson, R. S. (2018). Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease. In: M. W. Freeman & G. M. Saperia (Eds.). UpToDate. Waltham, MA: UpToDate.
  47. Schachter, S. C. (2018). Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects. In: P. Garcia & J. F. Dashe (Eds.). UpToDate. Waltham, MA: UpToDate.
  48. Shi, Y. W., Min, F. L., Zhou, D., Qin, B., Wang, J., Hu, F. Y., . . . Liao, W. P. (2017). HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology, 88, 2183-2191.
  49. Simon, R. H. (2019). Cystic fibrosis: Treatment with CFTR modulators. In: G. B. Mallory & A. G. Hoppin (Eds.). UpToDate. Waltham, MA: UpToDate.
  50. Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., . . . McNeish, I. A. (2018). Rucabarib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicenter, open-label, phase 3 trial. The Lancet Oncology, 18, I75-87.
  51. Tantry, U. S., Hennekens, C. H., Zehnder, J. L., & Gurbel, P. A. (2018). Clopidogrel resistance and clopidogrel treatment failure. In: L. L. K. Leung, D. Cutlip, & G. M. Saperia (Eds.). UpToDate. Waltham, MA: UpToDate.
  52. Wang, Y., Zhao, X., Lin, J., Li, H., Johnston, S. C., Lin, Y., . . . CHANCE Investigators. (2016). Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA, 316, 70-78.
  53. Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., . . . Edelson, M. I. (2016). Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. Gynecologic Oncology, 143, 3-15.
  54. Zeier, Z., Carpenter, L. L., Kalin, N. H., Rodriguez, C. I., McDonald, W. M., Widge, A. S., & Nemeroff, C. B. (2018). Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. American Journal of Psychiatry, 175, 873-886.

Go to

Policy activity

  • 10/18/2010 - Date of origin
  • 04/18/2019 - Effective date
Review date
  • 02/2019
Revision date
  • 04/05/2019

Related content